+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2019 to 2024

  • ID: 4756648
  • Report
  • 95 pages
  • Knowledge Sourcing Intelligence LLP
1 of 4


  • AdAlta Limited
  • Boehringer Ingelheim
  • Celdara Medical
  • Fibrogen Inc.
  • Galapagos NV
  • Hoffmann-La Roche
  • MORE
The global idiopathic pulmonary fibrosis treatment market is expected to reach US$4.020 billion by 2024 from US$2.090 billion in 2018, at a CAGR of 11.52%. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia characterized by the formation of scar tissue within the lungs in the absence of any known cause. The scarring typically starts at the edges of the lungs and advances towards the center of the lungs. As the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body. The disease initially manifests with symptoms of exercise-induced breathlessness and dry coughing. Diagnostic tests for IPF include chest imaging studies (X-Rays and CT scan), lung biopsy, pulmonary function tests, oxygen desaturation study and other tests such as autoantibody tests, full blood count, arterial blood gas etc. Currently there are two drugs approved for the treatment of IPF: Nintedanib and Pirfenidone. Both the drugs slow down the development of scar tissue in the lungs of people with IPF. Growth in prevalence of fibrotic disease coupled with the unavailability of proper treatment options will drive the market for the idiopathic pulmonary fibrosis treatment during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global idiopathic pulmonary fibrosis market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global idiopathic pulmonary fibrosis market.

Major industry players profiled as part of the report are Boehringer Ingelheim, Hoffmann-La Roche, Prometic Life Sciences Inc., and Fibrogen Inc. among others.


By Treatment type

Lung Transplant

By Gender


By Age Group

71 and above

By Geography

North America
United States

South America

United Kingdom

Middle East and Africa

Asia Pacific
Note: Product cover images may vary from those shown
2 of 4


  • AdAlta Limited
  • Boehringer Ingelheim
  • Celdara Medical
  • Fibrogen Inc.
  • Galapagos NV
  • Hoffmann-La Roche
  • MORE
1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base and Forecast Years Timeline

2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. Key Findings of the Study

4. Market Dynamics
4.1. Market Segmentation
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Porter's Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry In the Industry
4.6. Product Pipeline
4.7. Epidemiology

5. Idiopathic Pulmonary Fibrosis (Ipf) Treatment Market Forecast by Treatment Type
5.1. Medication
5.2. Lung Transplant

6. Idiopathic Pulmonary Fibrosis (Ipf) Treatment Market Forecast by Gender (Us$ Billion)
6.1. Male
6.2. Female

7. Idiopathic Pulmonary Fibrosis (Ipf) Treatment Market Forecast by Age Group (Us$ Billion)
7.1. 50-70
7.2. 71 and Above

8. Idiopathic Pulmonary Fibrosis (Ipf) Treatment Market Forecast by Geography (Us$ Billion)
8.1. North America
8.1.1. the U.S
8.1.2. Canada
8.2. South America
8.2.1. Brazil
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.4. Middle East and Africa
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. India

9. Competitive Intelligence
9.1. Competition and Offerings Analysis of Key Vendors
9.2. Strategies of Key Players
9.3. Recent Investments and Deals

10. Company Profiles
10.1. Boehringer Ingelheim
10.2. Hoffmann-La Roche
10.3. Lung Therapeutics
10.4. Fibrogen Inc.
10.5. Prometic Life Sciences Inc.
10.6. Samumed, Llc
10.7. Proterixbio, Inc
10.8. Galapagos Nv
10.9. Celdara Medical
10.10. Adalta Limited

List of Tables
List of Figures
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Boehringer Ingelheim
  • Hoffmann-La Roche
  • Lung Therapeutics
  • Fibrogen Inc.
  • Prometic Life Sciences Inc.
  • Samumed, LLC
  • ProterixBio, Inc
  • Galapagos NV
  • Celdara Medical
  • AdAlta Limited
Note: Product cover images may vary from those shown
5 of 4

The research study is based on the publisher's proprietary research model. The process involves sourcing of information from various industry experts, key professionals, decision-makers and various other stakeholders along with the validation of the responses received from the vast in-house database and premium paid databases. Publicly available sources were also taken into consideration for the final market estimates and forecast for the segments and sub-segments.

The first phase of the research process is the identification of key industry leaders, experts, decision-makers and C-level executives and then conducting interviews and surveys to gain vital insights about the market. Simultaneously, extensive secondary research is done, and key secondary data is collected as part of this process. This secondary data is collected from various databases, industry journals, whitepapers, company annual reports, research publications, and other paid data sources and relevant literature. Company profiles which include strategies, new product developments, recent investments, major products and services, financials and business plans are sourced from the annual reports, SEC filings, industry associations to preserve the quality of the information being displayed. The findings from both the primary and the secondary research process combined go under further processing for market breakdown and forecasting.

The last phase is providing intelligence in the form of presentation, charts, graphics and other different formats helping the clients in a faster and efficient understanding of the market. Under this phase complete market engineering is involved which includes analyzing the collected data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting. The publisher has developed their market forecasting methodology that, in addition to the main market values, also takes into account other macroeconomic factors (global or local) that might have some bearing on the market under study. Taking all the necessary data, a robust forecast is developed using an algorithm that involves both static (multivariate) as well as dynamic (time-series) regression analysis. Special care is taken to make sure their algorithm passes the necessary statistical tests, and the mean prediction for future years obtained is reliable with a very high confidence level. Following data validation, the analysts begin to write the report presenting insights with the help of charts, graphs, and tables.